middle.news
Cambium Bio Secures A$2.4M from Major Shareholder to Fuel Phase 3 Trials
8:28am on Tuesday 20th of January, 2026 AEDT
•
Healthcare
Read Story
Cambium Bio Secures A$2.4M from Major Shareholder to Fuel Phase 3 Trials
8:28am on Tuesday 20th of January, 2026 AEDT
Key Points
A$2.4 million placement at 20% premium to market price
ZYBT’s stake to rise from 28.1% to 39.6%, pending shareholder approval
Funds earmarked for initiating Phase 3 patient dosing and drug manufacturing
Phase 3 trials planned across US, Australia, and Taiwan with data expected in H2 2027
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE